FY2022 Q3 Financial and R&D Update

Alpha Clinical and Regulatory Progress YESCARTA ® (axicabtagene ciloleucel) (relapsed/refractory large B-cell lymphoma (LBCL), 2L) ■Dec 2022: Approved in Japan TARLIGE® (mirogabalin) (diabetic peripheral neuropathic pain (DPNP)) Jan 2023 Filing accepted in China DS-1211 (Pseudoxanthoma Elasticum (PXE) ) ■Nov 2022 : Ph2 study in PXE patients started DS-2325 (Netherton syndrome) ■Dec 2022: Granted Orphan Drug Designation by FDA Daiichi-Sankyo 31

View entire presentation